EpiPen

Mylan Finalizes $465 Million EpiPen Settlement
Mylan Finalizes $465 Million EpiPen SettlementThe settlement is the end of a long legal battle.
Express Scripts Kicks Out EpiPen Competitors
Express Scripts Kicks Out EpiPen CompetitorsBig changes for EpiPen and more in Express Scripts’ formulary.
Allergic Kids Aren’t Getting Enough Epinephrine
Allergic Kids Aren’t Getting Enough EpinephrineA new study shows that only a third of children suffering allergic reactions receive epinephrine immediately.
FDA approves EpiPen rivalAdamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.
Are EpiPens Still Good After Their Expiration Date?
Are EpiPens Still Good After Their Expiration Date?One pharmacist decided to find out how long an EpiPen stays useable.
MS Group Praises New Drug Despite High Price Tag
MS Group Praises New Drug Despite High Price TagWhy a drug that costs $65,000 a year is making patient groups happy.
EpiPen and EpiPen Jr. Recalled: Recall Expanded from Europe and AsiaTwo previous reports of device failures lead EpiPen maker to expand recall to the United States.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
EpiPens Recalled Overseas Due to Reported FailuresTwo device failures lead Mylan to recall more than 80,000 EpiPens overseas.
Insulin makers accused of price collusionU.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices.